Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance

Antiviral Research

Volumn 85, Issue 1, 2010, Pages 59-74

  Wensing, Annemarie M J ^a   van Maarseveen, Noortje M ^a   Nijhuis, Monique ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Drug resistance; HIV; Inhibitor; Protease; Therapy

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; GAG PROTEIN; GS 9350; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PLACEBO; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SPI 452; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CRYSTALLURIA; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME STRUCTURE; ENZYME SUBSTRATE; FATIGUE; FIRST PASS EFFECT; GASTROINTESTINAL DISEASE; GENE MUTATION; GENETIC VARIABILITY; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; KIDNEY DISEASE; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MULTIDRUG RESISTANCE; NAUSEA; NEPHROLITHIASIS; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VIROGENESIS; VIRUS INHIBITION; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS;

EID: 73549092917     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.10.003     Document Type: Review

References (166)

1. Abecasis A.B., Deforche K., Bacheler L.T., McKenna P., Carvalho A.P., Gomes P., Vandamme A.M., and Camacho R.J. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir. Ther. 11 (2006) 581-589
2. Abecasis A.B., Deforche K., Snoeck J., Bacheler L.T., McKenna P., Carvalho A.P., Gomes P., Camacho R.J., and Vandamme A.M. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 19 (2005) 1799-1806
3. Arvieux C., and Tribut O. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs 65 (2005) 633-659
4. Atkinson B., Isaacson J., Knowles M., Mazabel E., and Patick A.K. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine. J. Infect. Dis. 182 (2000) 420-427
5. Bartlett J.A., DeMasi R., Quinn J., Moxham C., and Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 15 (2001) 1369-1377
6. Bierman W.F., van Agtmael M.A., Nijhuis M., Danner S.A., and Boucher C.A. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 23 (2009) 279-291
7. Boyd M.A., Siangphoe U., Ruxrungtham K., Duncombe C.J., Stek M., Lange J.M., Cooper D.A., and Phanuphak P. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg QD in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Med. 6 (2005) 410-420
8. Boyd M.A., Srasuebkul P., Khongphattanayothin M., Ruxrungtham K., Hassink E.A., Duncombe C.J., Ubolyam S., Burger D.M., Reiss P., Stek Jr. M., Lange J., Cooper D.A., and Phanuphak P. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antivir. Ther. 11 (2006) 223-232
9. Bradbury R.A., and Samaras K. Antiretroviral therapy and the human immunodeficiency virus-improved survival but at what cost?. Diabetes Obes. Metab. 10 (2008) 441-450
10. Cahn P., Villacian J., Lazzarin A., Katlama C., Grinsztejn B., Arasteh K., Lopez P., Clumeck N., Gerstoft J., Stavrianeas N., Moreno S., Antunes F., Neubacher D., and Mayers D. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin. Infect. Dis. 43 (2006) 1347-1356
11. Callebaut C., Stray K., Tsai L., Xu l., Lee W., and Cihlar T. In vitro HIV-1 resistance selection to GS-8374, a novel phosphonate protease inhibitor: comparison with lopinavir, atazanavir and darunavir. Antivir. Ther. 12 (2007) S18
12. Cameron D.W., Heath-Chiozzi M., Danner S., Cohen C., Kravcik S., Maurath C., Sun E., Henry D., Rode R., Potthoff A., and Leonard J. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 351 (1998) 543-549
13. Cameron D.W., Japour A.J., Xu Y., Hsu A., Mellors J., Farthing C., Cohen C., Poretz D., Markowitz M., Follansbee S., Angel J.B., McMahon D., Ho D., Devanarayan V., Rode R., Salgo M., Kempf D.J., Granneman R., Leonard J.M., and Sun E. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13 (1999) 213-224
14. Cane P.A., de Ruiter A., Rice P., Wiselka M., Fox R., and Pillay D. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom. J. Clin. Microbiol. 39 (2001) 2652-2654
15. Cardiello P.G., Monhaphol T., Mahanontharit A., van Heeswijk R.P., Burger D., Hill A., Ruxrungtham K., Lange J.M., Cooper D.A., and Phanuphak P. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. J. Acquir. Immune Defic. Syndr. 32 (2003) 375-379
16. Clotet B., Bellos N., Molina J.M., Cooper D., Goffard J.C., Lazzarin A., Wohrmann A., Katlama C., Wilkin T., Haubrich R., Cohen C., Farthing C., Jayaweera D., Markowitz M., Ruane P., Spinosa-Guzman S., and Lefebvre E. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369 (2007) 1169-1178
17. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267 (1995) 483-489
18. Cohen C., Nieto-Cisneros L., Zala C., Fessel W.J., Gonzalez-Garcia J., Gladysz A., McGovern R., Adler E., and McLaren C. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr. Med. Res. Opin. 21 (2005) 1683-1692
19. Collier A.C., Coombs R.W., Schoenfeld D.A., Bassett R.L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V.J., Friedman H.M., Merigan T.C., Reichman R.C., Hooper C., and Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N. Engl. J. Med. 334 (1996) 1011-1017
20. Colonno R., Rose R., McLaren C., Thiry A., Parkin N., and Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J. Infect. Dis. 189 (2004) 1802-1810
21. Condra J.H., Holder D.J., Schleif W.A., Blahy O.M., Danovich R.M., Gabryelski L.J., Graham D.J., Laird D., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Yang T., Chodakewitz J.A., Deutsch P.J., Leavitt R.Y., Massari F.E., Mellors J.W., Squires K.E., Steigbigel R.T., Teppler H., and Emini E.A. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70 (1996) 8270-8276
22. Conradie F., Sanne I., Venter W., and Eron J. Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. AIDS 18 (2004) 1084-1085
23. Craig J.C., Duncan I.B., Hockley D., Grief C., Roberts N.A., and Mills J.S. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antivir. Res. 16 (1991) 295-305
24. Croom K.F., Dhillon S., and Keam S.J. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs 69 (2009) 1107-1140
25. Croom K.F., and Keam S.J. Tipranavir: a ritonavir-boosted protease inhibitor. Drugs 65 (2005) 1669-1677
26. Croteau G., Doyon L., Thibeault D., McKercher G., Pilote L., and Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71 (1997) 1089-1096
27. Dam E., Quercia R., Glass B., Descamps D., Launay O., Duval X., Krausslich H.G., Hance A.J., and Clavel F. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog. 5 (2009) e1000345
28. Dandache S., Sevigny G., Yelle J., Stranix B.R., Parkin N., Schapiro J.M., Wainberg M.A., and Wu J.J. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 51 (2007) 4036-4043
29. Danner S.A., Carr A., Leonard J.M., Lehman L.M., Gudiol F., Gonzales J., Raventos A., Rubio R., Bouza E., and Pintado V. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N. Engl. J. Med. 333 (1995) 1528-1533
30. Delaugerre C., Flandre P., Chaix M.L., Ghosn J., Raffi F., Dellamonica P., Jaeger H., Shürmann D., Cohen-Codar I., Van P.N., Norton M., Taburet A.M., Delfraissy J.F., and Rouzioux C. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob. Agents Chemother. 53 (2009) 2934-2939
31. De Meyer S., Azijn H., Fransen E., De Baere I., Van Ginderen M., Maes B., and de Bethune M.P. The pathway leading to TMC114 resistance is different for TMC114 compared with other protease inhibitors. Antivir. Ther. 11 (2006) S24
32. De Meyer S., Azijn H., Surleraux D., Jochmans D., Tahri A., Pauwels R., Wigerinck P., and de Bethune M.P. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49 (2005) 2314-2321
33. De Meyer S., Dierynck I., Lathouwers E., van Baelen B., Vangeneugden T., Spinosa-Guzman S., Peeters M., Picchio G., and de Bethune M.P. Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and DUET-2. Antivir Ther. 13 Suppl. 3 (2008) A33 (abstract no. 31)
34. De Meyer S., Lathouwers E., Dierynck I., De Paepe E., van Baelen B., Vangeneugden T., Spinosa-Guzman S., Lefebvre E., Picchio G., and de Bethune M.P. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS 23 14 (2009) 1829-1840
35. De Meyer S., Vangeneugden T., van Baelen B., De Paepe E., van Marck H., Picchio G., Lefebvre E., and de Bethune M.P. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res. Hum. Retrovir. 24 (2008) 379-388
36. Domingo E., Escarmis C., Sevilla N., Moya A., Elena S.F., Quer J., Novella I.S., and Holland J.J. Basic concepts in RNA virus evolution. FASEB J. 10 (1996) 859-864
37. Doyon L., Croteau G., Thibeault D., Poulin F., Pilote L., and Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70 (1996) 3763-3769
38. Doyon L., Tremblay S., Bourgon L., Wardrop E., and Cordingley M.G. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antivir. Res. 68 (2005) 27-35
39. Drusano G.L., Bilello J.A., Stein D.S., Nessly M., Meibohm A., Emini E.A., Deutsch P., Condra J., Chodakewitz J., and Holder D.J. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J. Infect. Dis. 178 (1998) 360-367
40. Emini E.A., Schleif W.A., Deutsch P., and Condra J.H. In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds. Adv. Exp. Med. Biol. 394 (1996) 327-331
41. Erickson-Viitanen S., Manfredi J., Viitanen P., Tribe D.E., Tritch R., Hutchison III C.A., Loeb D.D., and Swanstrom R. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res. Hum. Retrovir. 5 (1989) 577-591
42. Eron Jr. J., Yeni P., Gathe Jr. J., Estrada V., DeJesus E., Staszewski S., Lackey P., Katlama C., Young B., Yau L., Sutherland-Phillips D., Wannamaker P., Vavro C., Patel L., Yeo J., and Shaefer M. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368 (2006) 476-482
43. Fleury H.J., Toni T., Lan N.T., Hung P.V., Deshpande A., Recordon-Pinson P., Boucher S., Lazaro E., Jauvin V., Lavignolle-Aurillac V., Lebel-Binay S., Cheret A., and Masquelier B. Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data. AIDS Res. Hum. Retrovir. 22 (2006) 357-366
44. Frater A.J., Dunn D.T., Beardall A.J., Ariyoshi K., Clarke J.R., McClure M.O., and Weber J.N. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 16 (2002) 1139-1146
45. Friend J., Parkin N., Liegler T., Martin J.N., and Deeks S.G. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 18 (2004) 1965-1966
46. Gartland M. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients. Antivir. Ther. 6 (2001) 127-134
47. Gatanaga H., Suzuki Y., Tsang H., Yoshimura K., Kavlick M.F., Nagashima K., Gorelick R.J., Mardy S., Tang C., Summers M.F., and Mitsuya H. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J. Biol. Chem. 277 (2002) 5952-5961
48. Gathe J., Cooper D.A., Farthing C., Jayaweera D., Norris D., Pierone Jr. G., Steinhart C.R., Trottier B., Walmsley S.L., Workman C., Mukwaya G., Kohlbrenner V., Dohnanyi C., McCallister S., and Mayers D. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin. Infect. Dis. 43 (2006) 1337-1346
49. Gathe J., da Silva B.A., Cohen D.E., Loutfy M.R., Podzamczer D., Rubio R., Gibbs S., Marsh T., Naylor C., Fredrick L., and Bernstein B. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J. Acquir. Immune Defic. Syndr. 50 (2009) 474-481
50. Gathe Jr. J.C., Pierone G., Piliero P., Arasteh K., Rubio R., Lalonde R.G., Cooper D., Lazzarin A., Kohlbrenner V.M., Dohnanyi C., Sabo J., and Mayers D. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. AIDS Res. Hum. Retrovir. 23 (2007) 216-223
51. Gilliam B.L., Chan-Tack K.M., Qaqish R.B., Rode R.A., Fantry L.E., and Redfield R.R. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients. AIDS Patient Care STDS 20 (2006) 745-759
52. Giordano M., Kelleher T., Colonno R.J., Lazzarin A., and Squires K. The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons. J. Clin. Virol. 35 (2006) 420-425
53. Gonzalez L.M., Santos A.F., Abecasis A.B., van Laethem K., Soares E.A., Deforche K., Tanuri A., Camacho R., Vandamme A.M., and Soares M.A. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates. J. Antimicrob. Chemother. 61 (2008) 1201-1204
54. Grossman Z., Paxinos E.E., Averbuch D., Maayan S., Parkin N.T., Engelhard D., Lorber M., Istomin V., Shaked Y., Mendelson E., Ram D., Petropoulos C.J., and Schapiro J.M. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob. Agents Chemother. 48 (2004) 2159-2165
55. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Jonas L., Meibohm A., Holder D., Schleif W.A., Condra J.H., Emini E.A., Isaacs R., Chodakewitz J.A., and Richman D.D. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. J. Am. Med. Assoc. 280 (1998) 35-41
56. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Richman D.D., Valentine F.T., Jonas L., Meibohm A., Emini E.A., and Chodakewitz J.A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337 (1997) 734-739
57. Gulnik S., Eissenstat M., Afonina E., Ludtke D., Erickson J., Dagger R., Wynne B., and Guttendorf R. Preclinical and early clinical evaluation of SPI-452, a new pharmacokinetic enhancer. 16th Conference on Retroviruses and Opportunistic Infections (CROI) (2009) (ref type: abstract)
58. Gulnik S.V., and Eissenstat M. Approaches to the design of HIV protease inhibitors with improved resistance profiles. Curr. Opin. HIV AIDS 3 (2008) 633-641
59. Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., Eron Jr. J.J., Feinberg J.E., Balfour Jr. H.H., Deyton L.R., Chodakewitz J.A., and Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337 (1997) 725-733
60. Haubrich R., Thompson M., Schooley R., Lang W., Stein A., Sereni D., van der Ende M.E., Antunes F., Richman D., Pagano G., Kahl L., Fetter A., Brown D.J., and Clumeck N. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. AIDS 13 (1999) 2411-2420
61. Hicks C.B., Cahn P., Cooper D.A., Walmsley S.L., Katlama C., Clotet B., Lazzarin A., Johnson M.A., Neubacher D., Mayers D., and Valdez H. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368 (2006) 466-475
62. Hruz P.W. HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models. Curr. Opin. HIV AIDS 3 (2008) 660-665
63. Jacks T., Power M.D., Masiarz F.R., Luciw P.A., Barr P.J., and Varmus H.E. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331 (1988) 280-283
64. Jacobsen H., Haenggi M., Ott M., Duncan I.B., Andreoni M., Vella S., and Mous J. Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials. Antivir. Res. 29 (1996) 95-97
65. Johnson M., Grinsztejn B., Rodriguez C., Coco J., DeJesus E., Lazzarin A., Lichtenstein K., Rightmire A., Sankoh S., and Wilber R. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19 (2005) 685-694
66. Johnson M., Grinsztejn B., Rodriguez C., Coco J., DeJesus E., Lazzarin A., Lichtenstein K., Wirtz V., Rightmire A., Odeshoo L., and McLaren C. 96-Week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 20 (2006) 711-718
67. Johnson M.A., Gathe Jr. J.C., Podzamczer D., Molina J.M., Naylor C.T., Chiu Y.L., King M.S., Podsadecki T.J., Hanna G.J., and Brun S.C. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J. Acquir. Immune Defic. Syndr. 43 (2006) 153-160
68. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., and Richman D.D. Update of the drug resistance mutations in HIV-1. Top. HIV Med. 16 (2008) 138-145
69. Jordan P.S., Poon A., Eron J., Squires K., Ignacio C., Richman D.D., and Smith D.M. A novel codon insert in protease of clade B HIV type 1. AIDS Res. Hum. Retrovir. 25 (2009) 547-550
70. Katlama C., Esposito R., Gatell J.M., Goffard J.C., Grinsztejn B., Pozniak A., Rockstroh J., Stoehr A., Vetter N., Yeni P., Parys W., and Vangeneugden T. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 21 (2007) 395-402
71. Kempf D.J., King M.S., Bernstein B., Cernohous P., Bauer E., Moseley J., Gu K., Hsu A., Brun S., and Sun E. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J. Infect. Dis. 189 (2004) 51-60
72. Kempf D.J., Marsh K.C., Denissen J.F., McDonald E., Vasavanonda S., Flentge C.A., Green B.E., Fino L., Park C.H., and Kong X.P. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 2484-2488
73. Kempf D.J., Marsh K.C., Kumar G., Rodrigues A.D., Denissen J.F., McDonald E., Kukulka M.J., Hsu A., Granneman G.R., Baroldi P.A., Sun E., Pizzuti D., Plattner J.J., Norbeck D.W., and Leonard J.M. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41 (1997) 654-660
74. Kim E.Y., Winters M.A., Kagan R.M., and Merigan T.C. Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients. J. Virol. 75 (2001) 11227-11233
75. King N.M., Prabu-Jeyabalan M., Nalivaika E.A., Wigerinck P., de Bethune M.P., and Schiffer C.A. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 78 (2004) 12012-12021
76. Kinomoto M., Appiah-Opong R., Brandful J.A., Yokoyama M., Nii-Trebi N., Ugly-Kwame E., Sato H., Ofori-Adjei D., Kurata T., Barre-Sinoussi F., Sata T., and Tokunaga K. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin. Infect. Dis. 41 (2005) 243-251
77. Kitchen V.S., Skinner C., Ariyoshi K., Lane E.A., Duncan I.B., Burckhardt J., Burger H.U., Bragman K., Pinching A.J., and Weber J.N. Safety and activity of saquinavir in HIV infection. Lancet 345 (1995) 952-955
78. Koh Y., Nakata H., Maeda K., Ogata H., Bilcer G., Devasamudram T., Kincaid J.F., Boross P., Wang Y.F., Tie Y., Volarath P., Gaddis L., Harrison R.W., Weber I.T., Ghosh A.K., and Mitsuya H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47 (2003) 3123-3129
79. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimbach J.C., Dixon R.A., Scolnick E.M., and Sigal I.S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 4686-4690
80. Kozísek M., Sasková K.G., Rezácová P., Brynda J., van Maarseveen N.M., De Jong D., Boucher C.A., Kagan R.M., Nijhuis M., and Konvalinka J. Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region. J. Virol. 82 (2008) 5869-5878
81. Krausslich H.G., Ingraham R.H., Skoog M.T., Wimmer E., Pallai P.V., and Carter C.A. Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 807-811
82. Kurowski M., Sternfeld T., Sawyer A., Hill A., and Mocklinghoff C. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med. 4 (2003) 94-100
83. Leigh Brown A.J. Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 1862-1865
84. Leigh Brown A.J., and Richman D.D. HIV-1: gambling on the evolution of drug resistance?. Nat. Med. 3 (1997) 268-271
85. Madruga J.V., Berger D., McMurchie M., Suter F., Banhegyi D., Ruxrungtham K., Norris D., Lefebvre E., de Bethune M.P., Tomaka F., De Pauw M., Vangeneugden T., and Spinosa-Guzman S. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 370 (2007) 49-58
86. Maguire M.F., Guinea R., Griffin P., Macmanus S., Elston R.C., Wolfram J., Richards N., Hanlon M.H., Porter D.J., Wrin T., Parkin N., Tisdale M., Furfine E., Petropoulos C., Snowden B.W., and Kleim J.P. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 76 (2002) 7398-7406
87. Mammano F., Petit C., and Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J. Virol. 72 (1998) 7632-7637
88. Mammano F., Trouplin V., Zennou V., and Clavel F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 74 (2000) 8524-8531
89. Manosuthi W., Sungkanuparph S., Ruxrungtham K., Prasithsirikul W., Athichathanabadi C., Tantisiriwat W., Bowonwatanuwong C., Chumpathat N., and Chaovavanich A. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir. J. Acquir. Immune Defic. Syndr. 47 (2008) 127-129
90. Markowitz M., Conant M., Hurley A., Schluger R., Duran M., Peterkin J., Chapman S., Patick A., Hendricks A., Yuen G.J., Hoskins W., Clendeninn N., and Ho D.D. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J. Infect. Dis. 177 (1998) 1533-1540
91. Markowitz M., Saag M., Powderly W.G., Hurley A.M., Hsu A., Valdes J.M., Henry D., Sattler F., La M.A., and Leonard J.M. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333 (1995) 1534-1539
92. Martinez-Cajas J.L., Pant-Pai N., Klein M.B., and Wainberg M.A. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev. 10 (2008) 212-223
93. Martinez-Picado J., Savara A.V., Sutton L., and D'Aquila R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73 (1999) 3744-3752
94. Marzolini C., Buclin T., Decosterd L.A., Biollaz J., and Telenti A. Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Ther. Drug Monit. 23 (2001) 394-398
95. Mathez D., Bagnarelli P., Gorin I., Katlama C., Pialoux G., Saimot G., Tubiana P., De Truchis P., Chauvin J.P., Mills R., Rode R., Clementi M., and Leibowitch J. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy. Antivir. Ther. 2 (1997) 175-183
96. Mathias A., Lee M., Callebaut C., Xu L., Tsai L., Murray B., Liu H., Yale K., Warren D., and Kearney B. GS-9350: a pharmaco-enhancer without anti-HIV activity. 16th Conference on Retroviruses and Opportunistic Infections (CROI) (2009) (ref type: abstract)
97. McKeage K., Perry C.M., and Keam S.J. Darunavir: a review of its use in the management of HIV infection in adults. Drugs 69 (2009) 477-503
98. Mills A.M., Nelson M., Jayaweera D., Ruxrungtham K., Cassetti I., Girard P.M., Workman C., Dierynck I., Sekar V., Abeele C.V., and Lavreys L. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 23 13 (2009) 1679-1688
99. Mo H., King M.S., King K., Molla A., Brun S., and Kempf D.J. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J. Virol. 79 (2005) 3329-3338
100. Molina J.M., Andrade-Villanueva J., Echevarria J., Chetchotisakd P., Corral J., David N., Moyle G., Mancini M., Percival L., Yang R., Thiry A., and McGrath D. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 372 (2008) 646-655
101. Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P.J., Mo H.M., Markowitz M., Chernyavskiy T., Niu P., Lyons N., Hsu A., Granneman G.R., Ho D.D., Boucher C.A., Leonard J.M., Norbeck D.W., and Kempf D.J. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2 (1996) 760-766
102. Murphy R.L., Sanne I., Cahn P., Phanuphak P., Percival L., Kelleher T., and Giordano M. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 17 (2003) 2603-2614
103. Naeger L.K., and Struble K.A. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS 21 (2007) 179-185
104. Nalam M.N., and Schiffer C.A. New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors. Curr. Opin. HIV AIDS 3 (2008) 642-646
105. Navia M.A., Fitzgerald P.M.D., McKeever B.M., Leu C.T., Heimbach J.C., Herber W.K., Sigal I.S., Darke P.L., and Springer J.P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337 (1989) 615-620
106. Nijhuis M., Boucher C.A.B., Schipper P., Leitner T., Schuurman R., and Albert J. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease inhibitor therapy. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 14441-14446
107. Nijhuis M., Schuurman R., de Jong D., Erickson J., Gustchina E., Albert J., Schipper P., Gulnik S., and Boucher C.A.B. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13 (1999) 2349-2359
108. Nijhuis M., van Maarseveen N.M., de Jong D., Schipper P.J., Goedegebuure I.W., and Boucher C.A. Substitutions wihin Gag but outside the cleavage sites can cause protease inhibitor resistance. Antivir. Ther. 11 (2006) S149
109. Nijhuis M., van Maarseveen N.M., Lastere S., Schipper P., Coakley E., Glass B., Rovenska M., de Jong D., Chappey C., Goedegebuure I.W., Heilek-Snyder G., Dulude D., Cammack N., Brakier-Gingras L., Konvalinka J., Parkin N., Krausslich H.G., Brun-Vezinet F., and Boucher C.A. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med. 4 (2007) e36
110. Nijhuis M., Wensing A.M., Bierman W.F., de Jong D., Kagan R., Fun A., Jaspers C.A., Schurink K.A., van Agtmael M.A., and Boucher C.A. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. J. Infect. Dis 200 5 (2009) 698-709
111. Noble S., and Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52 (1996) 93-112
112. Notermans D.W., Jurriaans S., de Wolf F., Foudraine N.A., de Jong J.J., Cavert W., Schuwirth C.M., Kauffmann R.H., Meenhorst P.L., McDade H., Goodwin C., Leonard J.M., Goudsmit J., and Danner S.A. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group. AIDS 12 (1998) 167-173
113. Oldfield V., and Plosker G.L. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 66 (2006) 1275-1299
114. Partaledis J.A., Yamaguchi K., Tisdale M., Blair E.E., Falcione C., Maschera B., Myers R.E., Pazhanisamy S., Futer O., and Cullinan A.B. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69 (1995) 5228-5235
115. Patick A.K., Mo H., Markowitz M., Appelt K., Wu B., Musick L., Kalish V., Kaldor S., Reich S., Ho D., and Webber S. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40 (1996) 292-297
116. Paulsen D., Elston R., Snowden W., Tisdale M., and Ross L. Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects. J. Antimicrob. Chemother. 52 (2003) 319-323
117. Pellegrin I., Breilh D., Montestruc F., Caumont A., Garrigue I., Morlat P., Le C.C., Saux M.C., Fleury H.J., and Pellegrin J.L. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 16 (2002) 1331-1340
118. Pellegrin I., Breilh D., Ragnaud J.M., Boucher S., Neau D., Fleury H., Schrive M.H., Saux M.C., Pellegrin J.L., Lazaro E., and Vray M. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir. Ther. 11 (2006) 421-429
119. Perno C.F., Newcomb F.M., Davis D.A., Aquaro S., Humphrey R.W., Calio R., and Yarchoan R. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J. Infect. Dis. 178 (1998) 413-422
120. Petersen M.L., Wang Y., van der Laan M.J., Rhee S.Y., Shafer R.W., and Fessel W.J. Virologic efficacy of boosted double versus boosted single protease inhibitor therapy. AIDS 21 (2007) 1547-1554
121. Pettit S.C., Moody M.D., Wehbie R.S., Kaplan A.H., Nantermet P.V., Klein C.A., and Swanstrom R. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68 (1994) 8017-8027
122. Plosker G.L., and Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs 58 (1999) 1165-1203
123. Plosker G.L., and Scott L.J. Saquinavir: a review of its use in boosted regimens for treating HIV infection. Drugs 63 (2003) 1299-1324
124. Poppe S.M., Slade D.E., Chong K.T., Hinshaw R.R., Pagano P.J., Markowitz M., Ho D.D., Mo H., Gorman III R.R., Dueweke T.J., Thaisrivongs S., and Tarpley W.G. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 41 (1997) 1058-1063
125. Prabu-Jeyabalan M., Nalivaika E., and Schiffer C.A. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10 (2002) 369-381
126. Prado J.G., Wrin T., Beauchaine J., Ruiz L., Petropoulos C.J., Frost S.D., Clotet B., D'Aquila R.T., and Martinez-Picado J. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 16 (2002) 1009-1017
127. Quercia R., Garnier E., Ferre V., Morineau P., Bonnet B., Soulard C., and Raffi F. Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up. HIV Clin. Trials 6 (2005) 73-80
128. Quinones-Mateu M.E., and Arts E.J. HIV-1 fitness: implications for drug resistance, disease progression and global epidemic evolution. In: Kuiken C., Foley B., Hahn B., Marx P.A., McCutchan F., and Mellors J. (Eds). HIV Sequence Compendium 2001 (2001), Theoretical Biology and Biophysics Group, Los Alamos National Laboratory
129. Ramnathan S., Warren D., Wei L., and Kearney B.P. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir. 49th ICAAC (2009) (ref type: abstract)
130. Rhee S.Y., Gonzales M.J., Kantor R., Betts B.J., Ravela J., and Shafer R.W. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucl. Acids Res. 31 (2003) 298-303
131. Ribera E., Azuaje C., Lopez R.M., Diaz M., Feijoo M., Pou L., Crespo M., Curran A., Ocana I., and Pahissa A. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 20 (2006) 1131-1139
132. Riddler S.A., Haubrich R., DiRienzo A.G., Peeples L., Powderly W.G., Klingman K.L., Garren K.W., George T., Rooney J.F., Brizz B., Lalloo U.G., Murphy R.L., Swindells S., Havlir D., and Mellors J.W. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 358 (2008) 2095-2106
133. Ritonavir Package Insert. Supplement Number 023. 10-1-2008 (ref type: report).
134. Robinson B.S., Riccardi K.A., Gong Y.F., Guo Q., Stock D.A., Blair W.S., Terry B.J., Deminie C.A., Djang F., Colonno R.J., and Lin P.F. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44 (2000) 2093-2099
135. Rodriguez-French A., Boghossian J., Gray G.E., Nadler J.P., Quinones A.R., Sepulveda G.E., Millard J.M., and Wannamaker P.G. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 35 (2004) 22-32
136. Rodriguez-Novoa S., Morello J., Barreiro P., Maida I., Garcia-Gasco P., Vispo E., Gonzalez-Pardo G., Parra A., Jimenez-Nacher I., and Soriano V. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. AIDS Res. Hum. Retrovir. 24 (2008) 821-825
137. Saag M.S., Tebas P., Sension M., Conant M., Myers R., Chapman S.K., Anderson R., and Clendeninn N. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS 15 (2001) 1971-1978
138. Sadler B.M., Gillotin C., Lou Y., and Stein D.S. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob. Agents Chemother. 45 (2001) 30-37
139. Saskova K.G., Kozisek M., Rezacova P., Brynda J., Yashina T., Kagan R.M., and Konvalinka J. Molecular characterization of clinical isolates of HIV resistant to the protease inhibitor darunavir. J. Virol. 83 17 (2009) 8810-8818
140. + T-cell counts in HIV-infected patients. Ann. Intern. Med. 124 (1996) 1039-1050
141. Scherer J., Schapiro J., Maggiolo F., Perno C.F., Boucher C., Baxter J., Gellermann H., Tilke C., Santoro M.M., and Hall D.B. Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted mutation score. 7th European HIV Drug Resistance Workshop, March 25-27, 2009. Stockholm, Sweden (2009) (ref type: abstract)
142. Schmit J.C., Ruiz L., Clotet B., Raventos A., Tor J., Leonard J., Desmyter J., De Clercq E., and Vandamme A.M. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 10 (1996) 995-999
143. Schrader S., Chuck S.K., Rahn L.W., Parekh P., and Emrich K.G. Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules. AIDS Res. Ther. 5 (2008) 21
144. Sension M., Andrade Neto J.L., Grinsztejn B., Molina J.M., Zavala I., Gonzalez-Garcia J., Donnelly A., Phiri P., Ledesma E., and McGrath D. Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J. Acquir. Immune Defic. Syndr. 51 (2009) 153-162
145. Sham H.L., Kempf D.J., Molla A., Marsh K.C., Kumar G.N., Chen C.M., Kati W., Stewart K., Lal R., Hsu A., Betebenner D., Korneyeva M., Vasavanonda S., McDonald E., Saldivar A., Wideburg N., Chen X., Niu P., Park C., Jayanti V., Grabowski B., Granneman G.R., Sun E., Japour A.J., Leonard J.M., Plattner J.J., and Norbeck D.W. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42 (1998) 3218-3224
146. Smith G.H., Boulassel M.R., Klien M., Gilmore N., MacLeod J., LeBlanc R., Rene P., Routy J.P., and Lalonde R.G. Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients. HIV Clin. Trials 6 (2005) 63-72
147. Smith K.Y., Weinberg W.G., DeJesus E., Fischl M.A., Liao Q., Ross L.L., Pakes G.E., Pappa K.A., and Lancaster C.T. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res. Ther. 5 (2008) 5
148. Soulié C., Assoumou L., Ghosn J., Duvivier C., Peytavin G., Ait-Arkoub Z., Molina J.M., Costagliola D., Katlama C., Calvez V., and Marcelin A.G. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. AIDS 23 12 (2009) 1605-1608
149. Squires K., Lazzarin A., Gatell J.M., Powderly W.G., Pokrovskiy V., Delfraissy J.F., Jemsek J., Rivero A., Rozenbaum W., Schrader S., Sension M., Vibhagool A., Thiry A., and Giordano M. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. 36 (2004) 1011-1019
150. St Clair M.H., Millard J., Rooney J., Tisdale M., Parry N., Sadler B.M., Blum M.R., and Painter G. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antivir. Res. 29 (1996) 53-56
151. Stebbing J., Scourfield A., Koh G., Taylor C., Taylor S., Wilkins E., Gazzard B., Nelson M., and Jones R. A multicentre cohort experience with double-boosted protease inhibitors. J. Antimicrob. Chemother. 64 (2009) 434-435
152. Stein D.S., Fish D.G., Bilello J.A., Preston S.L., Martineau G.L., and Drusano G.L. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10 (1996) 485-492
153. Turner S.R., Strohbach J.W., Tommasi R.A., Aristoff P.A., Johnson P.D., Skulnick H.I., Dolak L.A., Seest E.P., Tomich P.K., Bohanon M.J., Horng M.M., Lynn J.C., Chong K.T., Hinshaw R.R., Watenpaugh K.D., Janakiraman M.N., and Thaisrivongs S. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. 41 (1998) 3467-3476
154. Ulbricht K., Stoll M., Behrens G., et al. Double protease inhibitor, RTI-sparing therapy regimen in naive HIV-1-infected patients: 24-week virologic response analysis of the LORAN trial. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 3-6, 2008 (2009) (ref type: abstract)
155. Vacca J.P., Dorsey B.D., Schleif W.A., Levin R.B., McDaniel S.L., Darke P.L., Zugay J., Quintero J.C., Blahy O.M., and Roth E. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4096-4100
156. van der Lugt J., Autar R.S., Ubolyam S., Garcia E.F., Sankote J., Avihingsanon A., Chuenyam T., Cooper D.A., Lange J., Phanuphak P., Wit F., Ruxrungtham K., and Burger D. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J. Antimicrob. Chemother. 61 (2008) 1145-1153
157. van de Vijver D.A., Wensing A.M., Angarano G., Asjö B., Balotta C., Boeri E., Camacho R., Chaix M.L., Costagliola D., De Luca A., Derdelinckx I., Grossman Z., Hamouda O., Hatzakis A., Hemmer R., Hoepelman A., Horban A., Korn K., Kücherer C., Leitner T., Loveday C., MacRae E., Maljkovic I., de Mendoza C., Meyer L., Nielsen C., Op de Coul E.L., Ormaasen V., Paraskevis D., Perrin L., Puchhammer-Stöckl E., Ruiz L., Salminen M., Schmit J.C., Schneider F., Schuurman R., Soriano V., Stanczak G., Stanojevic M., Vandamme A.M., Van Laethem K., Violin M., Wilbe K., Yerly S., Zazzi M., and Boucher C.A. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 41 (2006) 352-360
158. van Heeswijk R.P., Veldkamp A., Mulder J.W., Meenhorst P.L., Lange J.M., Beijnen J.H., and Hoetelmans R.M. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir. Ther. 6 (2001) 201-229
159. Voigt E., Wickesberg A., Wasmuth J.C., Gute P., Locher L., Salzberger B., Wohrmann A., Adam A., Weitner L., and Rockstroh J.K. First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. HIV Med. 3 (2002) 277-282
160. von Hentig N., Babacan E., Staszewski S., Stürmer M., Doerr H.W., and Lötsch J. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients. Antivir. Ther. 12 (2007) 1237-1246
161. Walmsley S., Avihingsanon A., Slim J., Ward D.J., Ruxrungtham K., Brunetta J., Bredeek U.F., Jayaweera D., Guittari C.J., Larson P., Schutz M., and Raffi F. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J. Acquir. Immune Defic. Syndr. 50 (2009) 367-374
162. Walmsley S., Bernstein B., King M., Arribas J., Beall G., Ruane P., Johnson M., Johnson D., Lalonde R., Japour A., Brun S., and Sun E. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346 (2002) 2039-2046
163. Wiegers K., Rutter G., Kottler H., Tessmer U., Hohenberg H., and Krausslich H.G. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J. Virol. 72 (1998) 2846-2854
164. Winters M.A., and Merigan T.C. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms. Antimicrob. Agents Chemother. 49 (2005) 2575-2582
165. Wlodawer A., Miller M., Jaskólski M., Sathyanarayana B.K., Baldwin E., Weber I.T., Selk L.M., Clawson L., Schneider J., and Kent S.B.H. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245 (1989) 616-621
166. Zhang Y.-M., Imamichi H., Imamichi T., Lane H.C., Falloon J., Vasudevachari M.B., and Salzman N.P. Drug Resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. J. Virol. 71 (1997) 6662-6670